PMP22 and demyelinating disease: Since CMT1A is a demyelinating disease, the myelination potential of the PMP22-transfected Schwann cells and the control-transfected and CRL-parent Schwann cell lines were investigated, which involved culturing the cell lines in the presence of a peptide containing the Epidermal Growth Factor (EGF)-Like domain and flanking regions of neuregulin 1 (NRG1) and also forskolin, using a method modified from that of others [32,33,41].